Latest & greatest articles for risperidone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on risperidone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on risperidone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for risperidone

61. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol

Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol Kongsakon R, Leelahanaj T, Price N (...) , Birinyi-Strachan L, Davey P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Several medications for schizophrenia were examined. The four atypical antipsychotics studied were olanzapine (OLZ), risperidone (RISP), quetiapine (QUET

2005 NHS Economic Evaluation Database.

62. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada

Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada Chue P S, Heeg B M, Buskens E, van Hout B A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared three treatment options for schizophrenia. The three treatment options differed in the starting treatment: haloperidol depot, a long-acting conventional antipsychotic agent, at a daily dose of 4.76 mg; long-acting risperidone, a long-acting atypical antipsychotic agent, at a daily dose of 2.3 mg; or oral risperidone, an oral

2005 NHS Economic Evaluation Database.

63. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US

Cost-effectiveness model of long-acting risperidone in schizophrenia in the US Cost-effectiveness model of long-acting risperidone in schizophrenia in the US Cost-effectiveness model of long-acting risperidone in schizophrenia in the US Edwards N C, Rupnow M F T, Pashos C L, Botteman M F, Diamond R J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of a long-acting injection (LAI) formulation of risperidone (RIS) for the treatment of patients with schizophrenia. Patients could receive LAI RIS 25 mg, 37.5 mg or 50 mg, given at 14-day intervals. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical cohort of community

2005 NHS Economic Evaluation Database.

64. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA

Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA Edwards N C, Locklear J C, Rupnow M F, Diamond R J Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared the following treatment options for patients with schizophrenia: long-acting risperidone, oral risperidone (average dose 3.8 mg/day), olanzapine (oral antipsychotic agent), long-acting injectable

2005 NHS Economic Evaluation Database.

65. Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database

Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database Zhao Z Y, Namjoshi M, Barber B L, Loosbrock (...) D L, Tunis S L, Zhu B J, Breier A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of atypical antipsychotic agents, olanzapine (OLZ) and risperidone (RIS), for the treatment of patients with schizophrenia. Type

2004 NHS Economic Evaluation Database.

66. [Longitudinal comparative study of risperidone vs classical neuroleptics in the treatment of schizophrenia: 24 months of observation]. (Abstract)

[Longitudinal comparative study of risperidone vs classical neuroleptics in the treatment of schizophrenia: 24 months of observation]. 12587355 2003 03 25 2015 11 19 0013-7006 28 Spec No 2 Pt 2 2002 Sep-Oct L'Encephale Encephale [Longitudinal comparative study of risperidone vs classical neuroleptics in the treatment of schizophrenia: 24 months of observation]. S31-2 Bouchard R H RH Polyclinique Sainte-Anne, 65, rue Sainte-Anne, 2e étage, Québec, G1R 3X5. fre Clinical Trial Comparative Study (...) Journal Article Randomized Controlled Trial Etude comparative longitudinale de la rispéridone versus les neuroleptiques classiques dans le traitement de la schizophrénie: 24 mois d'observation. France Encephale 7505643 0013-7006 L6UH7ZF8HC Risperidone U42B7VYA4P Chlorpromazine IM Adult Basal Ganglia Diseases chemically induced diagnosis Chlorpromazine adverse effects therapeutic use Cohort Studies Follow-Up Studies Humans Risperidone adverse effects therapeutic use Schizophrenia diagnosis drug therapy

2003 L'Encephale Controlled trial quality: uncertain

67. Depot risperidone for schizophrenia. (Abstract)

Depot risperidone for schizophrenia. Risperidone is the first new generation antipsychotic drug made available in a long acting injection.To examine the clinical effects of depot risperidone for people with schizophrenia and schizophrenia-like psychoses.We searched the Cochrane Schizophrenia Group's Register (December 2002), references of all included studies, and contacted industry and authors of included studies.Randomised clinical trials comparing depot risperidone with other treatments (...) for people with schizophrenia and/or schizophrenia-like psychoses.Two reviewers independently inspected citations and/or abstracts, ordered papers, re-inspected and quality assessed the results, and extracted data. For dichotomous data, we calculated the relative risk (RR), the 95% confidence interval (CI) and, where appropriate, the number needed to treat (NNT), on an intention-to-treat basis. For continuous data, we calculated weighted mean differences (WMD).One study (n=400) compared depot risperidone

2003 Cochrane

68. Risperdal (risperidone)

Risperdal (risperidone) Drug Approval Package: Risperdal (risperidone) NDA #021444 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Drug Review Package Risperdal (risperidone) Tablets Company: Johnson & Johnson Application No.: 021444 Approval Date: 4/2/2003 (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: July 15, 2003 Note: Documents in PDF format require the . - - Links on this page: Note: If you need help accessing information

2003 FDA - Drug Approval Package

69. Clinical trial response and dropout rates with olanzapine versus risperidone

Clinical trial response and dropout rates with olanzapine versus risperidone Clinical trial response and dropout rates with olanzapine versus risperidone Clinical trial response and dropout rates with olanzapine versus risperidone Santarlasci B, Messori A CRD summary This review assessed the use of olanzapine and risperidone for schizophrenia. The authors concluded that olanzapine appears to be associated with a lower drop-out rate than risperidone and it may improve long-term maintenance (...) of response, but further data on long-term maintenance are required. The authors' conclusions may not be reliable in view of the potential for various sources of bias. Authors' objectives To compare the drop-out and response rates between olanzapine and risperidone. Searching MEDLINE (from 1966 to May 2002), IDIS (from 1966 to May 2002) and the DRUGDEX databank (volume 112) were searched; the search terms were stated. Reference lists in identified studies were also reviewed. The search strategy

2003 DARE.

70. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis

Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis Taylor D M, Wright T, Libretto S E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two atypical antipsychotics for the first-line treatment of schizophrenia or schizoaffective disorders are compared: risperidone and olanzapine. Mean (+/- SD) doses were 5.5 (+/- 2.4) mg/day for risperidone and 14.1 (+/- 4.7) mg/day for olanzapine. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised

2003 NHS Economic Evaluation Database.

71. Cost-effectiveness of amisulpride compared with risperidone in patients with schizophrenia

Cost-effectiveness of amisulpride compared with risperidone in patients with schizophrenia Cost-effectiveness of amisulpride compared with risperidone in patients with schizophrenia Cost-effectiveness of amisulpride compared with risperidone in patients with schizophrenia Nicholls C J, Hale A S, Freemantle N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) for the AMIRIS study. There were 152 patients received amisulpride and 158 patients received risperidone. Study design The study was a randomised multi-centre clinical trial. The period of observation was 6 months of treatment, with the possibility of extension to 12 months. Analysis of effectiveness The basis of the analysis of effectiveness was intention to treat. The primary health outcome was assessed using the PANSS. The secondary health outcomes were assessed using the BPRS and the Clinical Global

2003 NHS Economic Evaluation Database.

72. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. Full Text available with Trip Pro

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. To quantify the association between olanzapine and diabetes.Population based nested case-control study.United Kingdom based General Practice Research Database comprising 3.5 million patients followed between 1987 and 2000.19 637 patients who had been diagnosed as having and treated for schizophrenia. 451 incident cases of diabetes were (...) matched with 2696 controls.Diagnosis and treatment of diabetes.Patients taking olanzapine had a significantly increased risk of developing diabetes than non-users of antipsychotics (odds ratio 5.8, 95% confidence interval 2.0 to 16.7) and those taking conventional antipsychotics (4.2, 1.5 to 12.2). Patients taking risperidone had a non-significant increased risk of developing diabetes than non-users of antipsychotics (2.2, 0.9 to 5.2) and those taking conventional antipsychotics (1.6, 0.7 to 3.8

2002 BMJ

73. Risperidone in children with autism and serious behavioral problems. (Abstract)

Risperidone in children with autism and serious behavioral problems. Atypical antipsychotic agents, which block postsynaptic dopamine and serotonin receptors, have advantages over traditional antipsychotic medications in the treatment of adults with schizophrenia and may be beneficial in children with autistic disorder who have serious behavioral disturbances. However, data on the safety and efficacy of atypical antipsychotic agents in children are limited.We conducted a multisite, randomized (...) , double-blind trial of risperidone as compared with placebo for the treatment of autistic disorder accompanied by severe tantrums, aggression, or self-injurious behavior in children 5 to 17 years old. The primary outcome measures were the score on the Irritability subscale of the Aberrant Behavior Checklist and the rating on the Clinical Global Impressions - Improvement (CGI-I) scale at eight weeks.A total of 101 children (82 boys and 19 girls; mean [+/-SD] age, 8.8+/-2.7 years) were randomly assigned

2002 NEJM Controlled trial quality: predicted high

74. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. (Abstract)

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. Prevention of relapse is a major goal of maintenance treatment in patients with psychotic disorders. We performed a long-term comparison of a newer, atypical antipsychotic drug, risperidone, and an older, conventional neuroleptic drug, haloperidol, in terms of the rate of relapse in patients with schizophrenia and schizoaffective disorder.In a double-blind, prospective study at 40 sites, we (...) randomly assigned adult outpatients in stable condition with chronic schizophrenia or schizoaffective disorder to receive treatment with flexible doses of either risperidone or haloperidol for a minimum of one year.Of the 397 patients who underwent randomization, data from 2 were excluded because they did not receive study medication; data from all 30 patients from one site were excluded by the sponsor, the Janssen Research Foundation, because of concern about the integrity of the data. The median

2002 NEJM Controlled trial quality: uncertain

75. A pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophrenia

A pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophrenia A pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophrenia A pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophrenia Hansen K, Francois C, Toumi M, Lancon C Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three treatments for schizophrenia were examined: zuclopenthixol (ZUC), a neuroleptic belonging to the family of thioxanthenes, which are conventional agents; haloperidol (HAL), another conventional agent; and risperidone (RIS), a new combined two-serotonin and two

2002 NHS Economic Evaluation Database.

76. Costs and outcomes of risperidone treatment in schizophrenia in the Czech Republic

Costs and outcomes of risperidone treatment in schizophrenia in the Czech Republic Costs and outcomes of risperidone treatment in schizophrenia in the Czech Republic Costs and outcomes of risperidone treatment in schizophrenia in the Czech Republic Hosak L, Bahbouh R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of risperidone versus standard neuroleptics in the treatment of schizophrenia. Standard neuroleptics comprised a combination of chlorpromazine, chlorprothixene, haloperidol, levomepromazine, oxyprothepine, perfenazine and thioridazine. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients aged between 18 and 65 years

2002 NHS Economic Evaluation Database.

77. Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications

Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications Jerrell J M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the use of two novel antipsychotic medications, risperidone and olanzapine, to treat people diagnosed with schizophrenia and schizoaffective disorder. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients aged between 18 and 54 years old with a diagnosis of schizophrenia or schizoaffective

2002 NHS Economic Evaluation Database.

78. The clinical value of risperidone and olanzapine: a meta-analysis of efficacy and safety

The clinical value of risperidone and olanzapine: a meta-analysis of efficacy and safety The clinical value of risperidone and olanzapine: a meta-analysis of efficacy and safety The clinical value of risperidone and olanzapine: a meta-analysis of efficacy and safety Peuskens J, De Hert M, Jones M Authors' objectives To synthesise the clinical trial data currently available on two novel antipsychotics, risperidone and olanzapine, and to compare them with conventional products in terms (...) of efficacy and safety. Searching MEDLINE, EMBASE, and PsycLIT were searched for articles published between January 1991 and June 1998. The search terms included both brand and generic names of all known antipsychotic medications used for the treatment of human schizophrenia. Study selection Study designs of evaluations included in the review Only randomised controlled trials, which involved either a risperidone or an olanzapine arm, were included in the review. The included studies reported the mean

2001 DARE.

79. Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia

Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia Oh P I, Lanctot K L, Mittmann N, Iskedjian M, Einarson T R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of risperidone (RIS) to ameliorate the negative symptoms of schizophrenia. Risperidone is a benzisoxazole derivative with combined serotonin and dopamine receptor blocking properties. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study population

2001 NHS Economic Evaluation Database.

80. Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS): health economic results of an international naturalistic study

Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS): health economic results of an international naturalistic study Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS): health economic results of an international naturalistic study Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS): health economic results of an international naturalistic study Kasper S, Jones M, Duchesne I Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of either risperidone or olanzapine for the treatment of patients with schizophrenia. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised hospitalised patients aged 65

2001 NHS Economic Evaluation Database.